Navigation Links
Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
Date:6/2/2008

trial for ANA773 in cancer patients in February and this study of ANA598 underway, Anadys is now focused on achieving important clinical milestones in both programs."

About ANA598

ANA598 is a highly potent and selective inhibitor of HCV genotypes 1a and 1b NS5b RNA polymerases (IC50 < 1 nM) and of HCV replication in cell culture (EC50 values for genotypes 1b and 1a replicons are 3 and 50 nM, respectively). ANA598 has been well-tolerated in all preclinical studies, including 28-day GLP toxicology studies, and was selected as a development candidate in June 2007.

Clinical Need and Market Opportunity in HCV Infection

Chronic hepatitis C virus (HCV) infection is a serious public health concern affecting approximately 2.7 million people in the United States and approximately 170 million people worldwide. HCV causes inflammation of the liver, which may lead to fibrosis and cirrhosis, liver cancer, and ultimately, liver failure. Cirrhosis of the liver resulting from chronic HCV infection is the leading indication for liver transplantation in the U.S. Due to the asymptomatic nature of HCV infection, it often goes undetected for up to 20 years following initial infection. Each year, 8,000 to 10,000 people in the U.S. die from complications of HCV.

The current standard of care is a combination of pegylated interferon and ribavirin. Inadequate response rates, in particular for patients infected with genotype 1 HCV, along with significant side effects of approved therapy, support the medical need for improved treatment options. It is estimated that fewer than 5% of people with chronic HCV infection living in the U.S. are under treatment today. The majority of infected individuals are unaware of their infection status and the large majority of individuals who know their status do not currently receive drug therapy. There is also a growing number of individuals who have failed interferon-based regimens who may be successfully treated with combi
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015  Xcelience, a contract development and ... made a structured cash investment in Powdersize, a ... milling, micronization and powder size classification within the ... business while simultaneously adding a complete set of ... capabilities. "As we continue to ...
(Date:7/31/2015)... and SAN DIEGO , July 31, ... company Eisai Co., Ltd. (Headquarters: Tokyo ... and Halozyme Therapeutics, Inc. (Headquarters: San Diego, ... Torley , "NASDAQ: HALO") have signed a clinical collaboration ... ® , "eribulin") in combination with Halozyme,s investigational drug ...
(Date:7/30/2015)... Edwards Lifesciences Corporation (NYSE: EW ), the global leader ... announced that Robert A. Ingram has retired from ... ardent champion for innovation in the lifesciences industry, and it ... board as we pursue our focused innovation strategy," said ... provided a valuable perspective to our board, drawing on his ...
Breaking Medicine Technology:Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6
... Oct. 14 The U.S. ... Planning and Evaluation (ASPE) has selected Thomson Reuters ... enable researchers to perform comparative effectiveness studies without ... (Logo: http://photos.prnewswire.com/prnh/20090507/NY12658LOGO ) (Logo: ...
... highlights the need for Anesthesia Information Management Systems (AIMS) ... access to day-of-surgery data is Extremely Important ... department.  More than half of the survey respondents are ... OR.  The independent survey of 277 anesthesiologists was sponsored ...
Cached Medicine Technology:Federal Government Selects Thomson Reuters to Build Tool That Streamlines Comparative Effectiveness Research 2New Survey Highlights Immediate Need for Anesthesia Information Management Systems 2New Survey Highlights Immediate Need for Anesthesia Information Management Systems 3
(Date:8/1/2015)... ... August 01, 2015 , ... Western University of ... profession” that comprises a growing percentage of U.S. physicians, and reflects the diversity ... one part of the message delivered by John W. Becher, DO, president of ...
(Date:8/1/2015)... ... , ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural Foods, was ... National Retail Federation, the largest retail trade association in the world, for her “advocacy ... to be named as such. According to the NRF’s website, Retail Champions are “Main ...
(Date:8/1/2015)... , ... August 01, 2015 , ... Lume Wellness creators ... is free to download on the Apple AppStore. , The app is designed ... mood, thus acting as a tool to view personal health and use this information ...
(Date:7/31/2015)... Rosa, CA (PRWEB) , ... July 31, 2015 ... ... posted by High Times magazine. What are the STASH awards? The Significant ... advances made by the cannabis-cultivation community as well as tried-and-true products that have ...
(Date:7/31/2015)... ... , ... Super Bowl 50 will emanate from Levi’s Stadium in Santa Clara, CA ... the Super Bowl. In the two weeks that separate the conference championships and the Super ... Super Bowl game will mark the 50th time it has been held and the festivities ...
Breaking Medicine News(10 mins):Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5Health News:Local Retail Advocate Wins National Recognition 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2
... 2008 /Xinhua-PRNewswire-FirstCall/ --,Linkwell Corporation (Linkwell or the Company) ... distributor of healthcare related,disinfectants in China, today announced ... a conference call on Wednesday, April 16, 2008, ... its 2007 year-end financial results on,Tuesday, April 15, ...
... Costs are rising on,everything from bread to education, and health ... nurse visits a Medicaid patient in the home, the,urgent need ... clear, according to nurses and other home care advocates,visiting legislators ... The cost of a nurse,s visit to a home ...
... Mark your calendars for these,training and networking ... Detroit Chapter (IABC/Detroit)!, April 16 Luncheon Session: ... organization,s message impact its market,share? Find out when ... messaging has impacted today,s marketing landscape., Join ...
... the University of Pennsylvania School of Medicine and colleagues ... two drugs bind to receptor sites on some tumors ... possibility of a new combination therapy for certain types ... tumors that have proteins called epidermal growth factor receptors ...
... Vulnerable for Rare,Metabolic Conditions, WASHINGTON, April 8, 2008 ... Bills to four consecutive Super,Bowls, will be on Capitol ... of Congress asking them to approve and fund the ... participate in a press event with Senators Christopher,Dodd and ...
... 2008 New,study results released today by the ... procedures performed by dermasurgeons are skin,cancer repair and ... Survey conducted among 3,176 ASDS,members, the top five ... Skin Cancer Repair and Reconstruction - 2,855,446/year, ...
Cached Medicine News:Health News:Linkwell Corporation Year-End 2007 Earnings Release and Conference Call Notice 2Health News:Bayada Nurses Advocates for Increase in Medicaid Reimbursement Rate to Allow More Individuals to Receive Home Care and Hire More Skilled Staff 2Health News:IABC/Detroit Announces April Professional Development and Networking Events 2Health News:Double binding sites on tumor target may provide future combination therapy 2Health News:Pro Football Hall of Fame Member Jim Kelly Urges Congress to Approve the Newborn Screening Saves Lives Act 2Health News:Pro Football Hall of Fame Member Jim Kelly Urges Congress to Approve the Newborn Screening Saves Lives Act 3Health News:Pro Football Hall of Fame Member Jim Kelly Urges Congress to Approve the Newborn Screening Saves Lives Act 4Health News:The American Society for Dermatologic Surgery Releases New Procedure Survey Data 2
MAGNETOM Symphony, an imaging system that offers 1.5T performance and top image quality in a short bore design....
... MAGNETOM Trio with Tim™ (Total ... workflow, highest speed, and highest resolution ... up to 16, advanced applications can ... routine. MAGNETOM Trio with Tim is ...
... It enables you to scan every beating heart ... radiation dose possible. A scanner using two ... time. It provides one-stop diagnosis in acute care; ... heart rate. Combined with the Cardiac Engine, a ...
... Assistant (MBA) is a Microsoft ... practice management software package. MBA ... Server technology and is HIPAA ... account receivable management, MBA allows ...
Medicine Products: